Clinical trial Recruiting at 1 site Interventional Ages 45 to 65

Mirror Therapy vs Motor Imagery to boost arm function after MCA stroke

Official title: Effects of Mirror Therapy and Motor Imagery on Upper Limb Motor Functions in Middle Cerebral Artery Stroke

Run by Lahore University of Biological and Applied Sciences · NCT07902284 · Data updated 2026-11-12

We’re testing whether mirror therapy or motor imagery added to standard Bobath-based therapy helps improve upper-limb function in adults 45-60 days after a middle cerebral artery stroke.

Quick facts

Study typeInterventional
Ages45 Years to 65 Years
SexAll
Enrollment36 (estimated)
SponsorLahore University of Biological and Applied Sciences
Academic / other
Locations1 site (Lahore, Punjab Province)
StatusRecruiting
StartedAugust 15, 2026
Main results expectedDecember 30, 2026
Study endsJanuary 30, 2027
Registry record updatedOctober 28, 2026
Trial IDNCT07902284 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 45-60 with a first-ever MCA stroke 1–6 months prior, unilateral upper-limb impairment, Brunnstrom stage II or higher, FMA-UE score below 47, and MoCA above 24.

Probably not a fit

Patients with very severe spasticity, significant cognitive impairment, or other major medical conditions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, single-blind study will assign 36 adults with a recent MCA stroke to receive either mirror therapy or motor imagery in addition to routine Bobath-based physical therapy, three supervised sessions per week for six weeks followed by a home program. Outcomes will include the Fugl-Meyer Upper Extremity score, ARAT, Box and Block Test, and Modified Barthel Index, measured at baseline, after treatment, and at 12 weeks. The goal is to determine which adjunct yields greater and longer-lasting motor improvements for the affected arm. The trial is conducted at Alfalah Medical Center in Lahore, Pakistan, with participants selected based on specific upper-limb impairment criteria and stable medical status.

Why it matters

Potential benefit: If successful, participants could experience greater restoration of arm function and independence in daily activities.

How similar studies have gone: Previous reviews suggest MT and MI can improve motor outcomes, but direct comparisons in MCA stroke with Bobath therapy are limited; this study addresses a gap with direct comparison.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients of both genders aged 45-60 years
* First-ever middle cerebral artery (MCA) stroke (ischemic or hemorrhagic) confirmed by CT/MRI
* Stroke duration of 1-6 months
* Presence of unilateral upper limb motor impairment
* Brunnstrom stage II and above
* Fugl-Meyer Assessment Upper Extremity (FMA-UE) score \< 47
* Montreal Cognitive Assessment (MoCA) \> 24
* Medically stable
* Willing and able to provide written informed consent

Exclusion Criteria:

* Pre-existing upper limb dysfunction
* Visual impairment or unilateral neglect
* Severe cognitive impairment or depression
* Other neurological disorders
* Severe musculoskeletal disorders of the upper limb
* Severe spasticity (Modified Ashworth Scale \> 3)
* Serious uncontrolled medical conditions
* Participation in another clinical trial
* Refusal or inability to provide

Where it's running

  • Alfalah Medical Center
    Lahore, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.